Markets:

Overview

News

Currencies

International

Treasuries

BioNTech SE - American Depositary Shares (NQ:BNTX)

92.44 +1.51 (+1.67%)

Streaming Delayed Price Updated: 3:21 PM EDT, May 22, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BioNTech SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

72 73 Next >

BioNTech Stock: A Deep Dive Into Analyst Perspectives (6 Ratings) ↗

April 01, 2025

Via Benzinga

European Patent Office Rules Vaccine Developer CureVac's Amended Patent Valid, Stock Jumps ↗

March 28, 2025

CureVac's amended patent survives BioNTech's challenge as EPO upholds validity. A German court will decide on infringement in July 2025.

Via Benzinga

Topics Intellectual Property

4 Analysts Have This To Say About BioNTech ↗

March 11, 2025

Via Benzinga

BioNTech's 2025 Revenue View, Vaccine Policy Uncertainty Prompt Price-Target Cut: Retail Stays Cautiously Optimistic ↗

March 10, 2025

For the current year, BioNTech projected revenue of 1.7 billion euros to 2.2 billion euros, below the market consensus of 2.54 billion euros and a fall from last year's 2.75 billion euros.

Via Stocktwits

BioNTech Se (BNTX) Q4 2024 Earnings Call Transcript ↗

March 10, 2025

BNTX earnings call for the period ending December 31, 2024.

Via The Motley Fool

Topics Earnings

Peering Into BioNTech's Recent Short Interest ↗

January 28, 2025

Via Benzinga

Why BioNTech (BNTX) Shares Are Volatile Today ↗

January 13, 2025

Shares of BioNTech fell 4% on Monday. Vaccine stocks are volatile after Moderna's updated revenue guidance for 2025, which fell below analyst expectations.

Via Benzinga

Nasdaq, S&P 500 Hit 6-Month Lows As Recession Fears Grow: What's Driving Markets Monday? ↗

March 10, 2025

Stocks extended last week's losses on Monday as concerns over the U.S. economy continue to weigh on the market. The Nasdaq 100 saw the steepest declines, with Tesla, Inc. (NASDAQ:TSLA) and Palantir...

Via Benzinga

Topics Economy Stocks

Pfizer's COVID-19 Shot Partner BioNTech Reports Q4 Profit, But 2025 Guidance Falls Short On Expectations ↗

March 10, 2025

BioNTech's Q4 revenue beat estimates despite lower COVID-19 vaccine sales. The company advances oncology programs, with key data updates expected in 2025.

Via Benzinga

BioNTech Surpasses Q4 Revenue Estimates ↗

March 10, 2025

BioNTech SE exceeded earnings expectations with strong oncology pipeline development, despite reduced vaccine revenue.

Via The Motley Fool

US Stocks Likely To Open Lower After Trump Hints At Looming Recession: Expert Says Can't Rule Out A Bear Market As Indices Inch Towards Correction Territory ↗

March 10, 2025

U.S. stock futures declined on Monday after a small bout of relief on Friday as indices neared the correction zone.

Via Benzinga

Topics Government

BioNTech Announces Fourth Quarter and Full Year 2024 Financial Results and Corporate Update

March 10, 2025

From BioNTech SE

Via GlobeNewswire

Earnings Scheduled For March 10, 2025 ↗

March 10, 2025

Via Benzinga

Dow Gains Over 200 Points But Records Weekly Loss: Fear Among Investors Eases But Greed Index Remains In 'Extreme Fear' Zone ↗

March 10, 2025

Via Benzinga

Topics Stocks

BioNTech, Oracle And 3 Stocks To Watch Heading Into Monday ↗

March 10, 2025

Via Benzinga

Nasdaq Falls Into Correction As Tariffs Roil Wall Street: What's Moving Markets Friday? ↗

March 07, 2025

All three major indices were red in Friday’s midday trading, with the S&P 500 and Nasdaq 100 down 1% and 1.24%, respectively, and on track for their worst weeks since September 2024.

Via Benzinga

Why Moderna Stock Has Surged 20% This Week Despite Mixed News ↗

March 07, 2025

Recent news has been mixed with a patent win and loss in Germany and the U.S. But Moderna stock has risen markedly this week.

Via Investor's Business Daily

Topics Intellectual Property

BioNTech Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call ↗

March 07, 2025

Via Benzinga

FDA Places Clinical Hold On BioNTech's Early-Phase Trial For RNA-Based Malaria Vaccine ↗

March 05, 2025

BioNTech's malaria vaccine trial faces an FDA clinical hold. The company is addressing concerns and collaborating with regulators on next steps.

Via Benzinga

BioNTech to Report Fourth Quarter and Full Year 2024 Financial Results and Corporate Update on March 10, 2025

February 24, 2025

From BioNTech SE

Via GlobeNewswire

Electronic Arts Posts Upbeat Earnings, Joins Mattel, Johnson Controls, Mueller Water Products And Other Big Stocks Moving Higher On Wednesday ↗

February 05, 2025

Via Benzinga

RFK Jr. Clears A Key Hurdle To Head Up HHS. Why His Nomination Is A Biotech Black Box. ↗

February 04, 2025

RFK Jr. cleared a key hurdle Tuesday after the Senate Finance Committee voted along party lines in favor of his nomination.

Via Investor's Business Daily

Pfizer Edges Higher As Covid Sales Decline, But Still Beat Expectations ↗

February 04, 2025

Pfizer stock rose moderately early Tuesday on the back of its quarterly beat.

Via Investor's Business Daily

BioNTech Completes Acquisition of Biotheus

February 03, 2025

From BioNTech SE

Via GlobeNewswire

Moderna Yo-Yos After European Officials Ink Supply Deal For Covid Shots ↗

January 24, 2025

Moderna won an agreement for its Covid vaccines in Europe on Friday, but Moderna stock reversed its early gains.

Via Investor's Business Daily

3 Dirt-Cheap Stocks to Buy in a Market That's Priced for Perfection ↗

January 22, 2025

Via The Motley Fool

Moderna, GameStop And Snap Are Among Top Large-Cap Losers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio? ↗

January 19, 2025

Eleven large-cap stocks were the worst performers in the last week. Short positions announced for FTAI, revenue updates for MRNA, and price forecasts changed for GME, SNAP, RKLB, NTRA, LLY, ICLR, BNTX,...

Via Benzinga

Moderna Has Lost 94% Of Its Value Over Four Years. Is It A Sell? ↗

January 14, 2025

Shares hit another skid on Jan. 13 when the company cut its guidance for 2024 and 2025.

Via Investor's Business Daily

BioNTech Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference

January 14, 2025

From BioNTech SE

Via GlobeNewswire

BioNTech Positioned For Solid Growth Amid Oncology Transition: Analyst ↗

January 10, 2025

Truist rates BioNTech a Buy, citing its shift to oncology with BNT327 leading the way. Key data updates and growth catalysts are expected by 2025.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

72 73 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.